Brian’s Story: Finding a Treatment for Type 1 Gaucher

By National Gaucher FoundationNov 25, 2016

This post is sponsored content. The Forward’s editorial staff were not involved in its publication.

Brian Berman is president and chief executive officer of the National Gaucher Foundation (NGF). Diagnosed at the age of 4 with Type 1 Gaucher disease after suffering critical and worsening symptoms, Mr. Berman’s initial prognosis was grim. His parents refused to watch their son die without a fight. They found Dr. Roscoe Brady, who was then leading groundbreaking research on Gaucher disease treatment. Mr. Berman, an ideal clinical trial candidate, became the first person in the world to successfully receive enzyme replacement therapy for Gaucher disease.

The National Gaucher Foundation (NGF) is an independent nonprofit organization that serves U.S. patients with Gaucher disease and their families.

A message from our CEO & publisher Rachel Fishman Feddersen

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

The coming year promises to be filled with more complex and historic developments. We are entering an era where independent, fact-based Jewish journalism will be more important than ever. We need to be ready for whatever 2025 will bring, and with your help, we can be.

We’ve set a goal to raise $260,000 by December 31. That’s an ambitious goal, but one that will give us the resources we need to invest in the high quality news, opinion, analysis and cultural coverage that isn’t available anywhere else.

If you feel inspired to make an impact, now is the time to give something back. Join us as a member at your most generous level.

— Rachel Fishman Feddersen, Publisher and CEO